We further utilized RNA-seq data from the same TARGET neuroblastoma cohort to analyze 1044 transcripts from the 17q21-ter locus for all of the following five criteria (Fig. 1d): differential gene expression in (1) 17q21-ter-gain patients (Supplementary Data 1) and (2) MYCN-amplified patients (Supplementary Table 1), correlation with (3) gene copy number (Supplementary Data 2) and (4) MYCN expression (Supplementary Table 2), as well as (5) association with poor neuroblastoma patient outcome (Supplementary Table 3). Here, MYCN is linked to neuroblastoma.